Trial reportThe Permanente journal2020
High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial.
Trial report in The Permanente journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Association between adherence to Mediterranean-DASH intervention for neurodegenerative delay diet and disease severity in patients with ulcerative colitis.Scientific reports · 2025Article
- Reduced Sulfur Diet Reshapes the Microbiome and Metabolome in Mild-Moderate Ulcerative Colitis.International journal of molecular sciences · 2025Article
- Severe ulcerative colitis: diagnostic criteria and therapy.Journal of gastroenterology · 2025Article
- Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective.Nutrition journal · 2025Review
- Long-term durability of infliximab maintenance therapy incorporating plant-based diet in inflammatory bowel disease.Translational gastroenterology and hepatology · 2025Article
- Association between plant-based dietary index and disease severity in patients with ulcerative colitis: a cross-sectional study.BMC gastroenterology · 2024Article
- Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy.Journal of gastroenterology · 2024Article
- Revolution in diet therapy for inflammatory bowel disease.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Plant-based diet for pregnant women with inflammatory bowel disease: case series.Translational gastroenterology and hepatology · 2024Article
- Review
- Incorporation of Plant-Based Diet Surpasses Current Standards in Therapeutic Outcomes in Inflammatory Bowel Disease.Metabolites · 2023Review
- Dietary Exposures and Interventions in Inflammatory Bowel Disease: Current Evidence and Emerging Concepts.Nutrients · 2023Review
- Therapeutic advancement in inflammatory bowel disease by incorporating plant-based diet.Translational gastroenterology and hepatology · 2023Review
- Dietary Patterns and Gut Microbiota Changes in Inflammatory Bowel Disease: Current Insights and Future Challenges.Nutrients · 2022Review
- Relapse-Free Course in Nearly Half of Crohn's Disease Patients With Infliximab and Plant-Based Diet as First-Line Therapy: A Single-Group Trial.The Permanente journal · 2022Article
- Stepwise Treatment With Plant-Based Diet and Medication for Patient With Mild Ulcerative Colitis.The Permanente journal · 2021Article
- Increased Incidence of Inflammatory Bowel Disease in Association with Dietary Transition (Westernization) in Japan.JMA journal · 2021Article
- A Whole Food Plant-Based Approach to Ulcerative Colitis; A Case Series.American journal of lifestyle medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAbout one-third of patients with severe ulcerative colitis (UC) do not respond to corticosteroid therapy and receive rescue therapy with infliximab or cyclosporine. Up to 20% of such patients fail to respond to rescue therapy and undergo colectomy.
objectiveWe investigated the outcomes of infliximab and a plant-based diet (PBD) as first-line therapy for severe UC.
methodsPatients with severe UC defined by the Truelove and Witts criteria were admitted and given standard induction therapy with infliximab (5.0 mg/kg-7.5 mg/kg) at 0, 2, and 6 weeks. Additionally, they received a PBD. The primary endpoint was remission or colectomy in the induction phase and 1 year after discharge. Secondary endpoints were changes in inflammatory markers in the induction phase and the PBD score at baseline and follow-up. A higher PBD score indicates greater adherence to a PBD.
resultsInfliximab and PBD as first-line therapy was administered in 17 cases. The remission rate was 76% (13/17), and the colectomy rate was 6% (1/17) in the induction phase. C-reactive protein values and the erythrocyte sedimentation rate significantly decreased at week 6 from 9.42 mg/dL to 0.33 mg/dL and from 59 to 17 mm/h, respectively (p < 0.0001). At 1-year follow-up, the cumulative relapse rate was 25%, and there were no additional colectomy cases. Mean PBD scores of 27.7 at 1 year and 23.8 at 4 years were significantly higher than baseline scores of 8.3 and 9.9, respectively (p < 0.0001 and p = 0.0391).
conclusionThis new first-line therapy for severe UC demonstrated a higher remission rate and lower colectomy rate than with the current modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.